Actively Recruiting
Nerve Excitability in Cisplatin-Induced Peripheral Neuropathy
Led by Ka-Wai Ho · Updated on 2026-04-22
60
Participants Needed
2
Research Sites
152 weeks
Total Duration
On this page
Sponsors
K
Ka-Wai Ho
Lead Sponsor
D
Dana-Farber Cancer Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to evaluate nerve excitability in participants with cisplatin-induced peripheral neuropathy (cis-PN) using threshold tracking nerve conduction studies (TTNCS). By assessing changes in nerve excitability parameters, the study seeks to enhance understanding of the pathophysiology of cis-PN and identify early markers of neurotoxicity in participants undergoing cisplatin-based chemotherapy.
CONDITIONS
Official Title
Nerve Excitability in Cisplatin-Induced Peripheral Neuropathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults age 218 who will begin cisplatin-based chemotherapy alone or with other agents not known to cause neuropathy (Cohort A)
- Adults age 218 with diagnosed cisplatin-induced peripheral neuropathy, with last cisplatin dose at least 3 months prior (Cohort B)
- Participants must have adequate blood counts to receive chemotherapy (Cohort A)
You will not qualify if you...
- Pre-existing peripheral neuropathy
- Family history of genetic or familial neuropathy
- Contraindication to cisplatin treatment as determined by primary oncologist (Cohort A)
- Chemotherapy combining cisplatin with other agents known to cause neuropathy (Cohort A)
- Presence of cardiac or spinal stimulating devices
- Women who are pregnant or breastfeeding
- Adults unable to provide informed consent or complete neuropathy symptom questionnaires
- Other medical conditions making study participation hazardous
- Patients unlikely to comply with study protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
Actively Recruiting
2
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Not Yet Recruiting
Research Team
K
Ka-Wai Ho, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here